Confound, Cause, or Cure: The Effect of Cannabinoids on HIV-Associated Neurological Sequelae.

The persistence of human immunodeficiency virus-1 (HIV)-associated neurocognitive disorders (HAND) in the era of effective antiretroviral therapy suggests that modern HIV neuropathogenesis is driven, at least in part, by mechanisms distinct from the viral life cycle. Identifying more subtle mechanisms is complicated by frequent comorbidities in HIV+ populations. One of the common confounds is substance abuse, with cannabis being the most frequently used psychoactive substance among people living with HIV. The psychoactive effects of cannabis use can themselves mimic, and perhaps magnify, the cognitive deficits observed in HAND; however, the neuromodulatory and anti-inflammatory properties of cannabinoids may counter HIV-induced excitotoxicity and neuroinflammation. Here, we review our understanding of the cross talk between HIV and cannabinoids in the central nervous system by exploring both clinical observations and evidence from preclinical in vivo and in vitro models. Additionally, we comment on recent advances in human, multi-cell in vitro systems that allow for more translatable, mechanistic studies of the relationship between cannabinoid pharmacology and this uniquely human virus.

A regulatory take on cannabis and cannabinoids for medicinal use in the European Union.

The discovery of the endocannabinoid system has raised public interest in the medicinal use of cannabis, phytocannabinoids, and synthetic cannabinoids, which has always been closely regulated due to their psychotropic effects and potential abuse. The review takes a quick look at the current legal framework in the European Union, which regulates cannabis use and cultivation for medicinal purposes in line with the United Nations Conventions on the production, trade, and use of cannabis, phytocannabinoids, and synthetic cannabinoids. And while the EU legislation precisely defines requirements and marketing authorisation procedures for medicinal products for all EU member states, there is no common regulatory framework for magistral and officinal preparations containing cannabinoids, as they are exempt from marketing authorisation. Instead, their regulation is left to each member state, and it is quite uneven at this point, mainly due to cultural and historical differences between the countries, leading to different access to non-authorised medicinal products. Therefore, to meet great public interest, harmonised approaches on cannabinoid-containing products without marketing authorisation would be welcome to level the playing field in the EU.

The effect of Clinical Practice Guidelines on prescribing practice in mental health: A systematic review.

Clinical Practice Guidelines are succinct evidence-based recommendations and in psychiatry, exist to advise on psychotropic prescribing to effectively treat mental health conditions whilst minimising medication adverse effects. Implementation of psychiatric guidelines have, in the past, demonstrated little and transient impact on clinical practice. How effective prescribing guidelines are in aligning practice with evidence currently is unknown and this systematic review aimed to investigate said efficacy. Literature searches were performed on MEDLINE, EMBASE, and CINAHL up to September 2019 and articles were selected by two reviewers independently with discrepancies resolved by a third reviewer. The review identified 18 eligible articles pertaining to the following conditions: depressive disorders, psychotic disorders, post-traumatic stress disorder, anxiety disorders, bipolar affective disorder, attention deficit/hyperactivity disorder, borderline personality disorder, and opiate addiction with depression guidelines being the most frequently evaluated. Seven studies revealed guidelines effected no change in psychotropic prescribing. The remaining studies illustrated that even when practice was changed, the effect was generally small, emphasising the need to change guideline development and implementation, taking into account obstacles or opportunities specific to psychotropic pharmacotherapy.

Use of psychoactive substances in women in outpatient treatment.

OBJECTIVE: to characterize the sociodemographic and psychiatric profile of women users of psychoactive substances in treatment for drug addiction. METHOD: descriptive study of quantitative approach performed with women attended at a Psychosocial Care Center for Users of Alcohol and Other Drugs (CAPS ad) from the interior of São Paulo State. RESULTS: the sample consisted of 349 adult women, single, low educational level and unemployed, users of alcohol, cocaine, crack and tranquillizers. Among the consequences of use include withdrawal syndrome, overdose, depressive and suicidal symptoms. Most were referred for treatment by the family or health services. Almost 20% of these women had previously started treatments. CONCLUSION: The results suggest marked morbidity and high levels of psychosocial vulnerability, which require thorough investigation at the patient's admission, as well as damage associated with use, withdrawal symptoms and depressive symptoms.

[Dropout from Specialty Training is determined by the perception of autonomy and treatment efficacy]. / 6 av 10 ST-läkare på BUP funderar på att hoppa av - Upplevelse av brist på effektiv psykologisk behandling och låg autonomi på arbetsplatsen främsta orsaker.

The Swedish Association for Child and Adolescent Psychiatry conducted a survey among their specialty trainees in 2018. Of the 48% response rate, around 48% admitted hesitancy to continue in their chosen specialty. A further 12% planned to depart from their field after completion of training. Factors associated with discontinuation in training were the perception of ineffective psychotherapeutic treatments and a lack of autonomy at work; which was strongly correlated to the doctor's role and team collaboration. Workload was generally perceived as excessive, with not enough time for after work recovery and the subsequent negative impact on private life. However, these factors were not found to significantly affect trainees' decision to leave. The doctor's role requires better clarification and medical leadership needs to be improved, so that evidence based treatments can be offered.

Use of psychoactive substances in women in outpatient treatment / Uso de sustancias en mujeres en tratamiento ambulatorio / Uso de substâncias psicoativas em mulheres em tratamento ambulatorial

ABSTRACT Objective: to characterize the sociodemographic and psychiatric profile of women users of psychoactive substances in treatment for drug addiction. Method: descriptive study of quantitative approach performed with women attended at a Psychosocial Care Center for Users of Alcohol and Other Drugs (CAPS ad) from the interior of São Paulo State. Results: the sample consisted of 349 adult women, single, low educational level and unemployed, users of alcohol, cocaine, crack and tranquillizers. Among the consequences of use include withdrawal syndrome, overdose, depressive and suicidal symptoms. Most were referred for treatment by the family or health services. Almost 20% of these women had previously started treatments. Conclusion: The results suggest marked morbidity and high levels of psychosocial vulnerability, which require thorough investigation at the patient's admission, as well as damage associated with use, withdrawal symptoms and depressive symptoms.

RESUMEN Objetivo: caracterizar el perfil sociodemográfico y psiquiátrico de mujeres usuarias de sustancias psicoactivas en tratamiento para la dependencia química. Método: estudio descriptivo de abordaje cuantitativo realizado con mujeres atendidas en un Centro de Atención Psicosocial para Usuarios de Alcohol y otras Drogas (CAPS ad) del interior paulista. Resultados: la muestra fue de 349 mujeres adultas, solteras, baja escolaridad y desempleadas, usuarias de alcohol, cocaína, crack y tranquilizantes. Entre las consecuencias del uso incluyen el síndrome de abstinencia, sobredosis, síntomas depresivos y suicidas. La mayoría fueron encaminadas para el tratamiento por la familia o los servicios de salud. Casi el 20% de estas mujeres ya habían iniciado tratamientos anteriormente. Conclusión: Los resultados sugieren acentuada morbilidad y altos niveles de vulnerabilidad psicosocial, que requieren una investigación minuciosa en la admisión de la usuaria, además de daños asociados al uso, síntomas de abstinencia y síntomas depressivos.

RESUMO Objetivo: caracterizar o perfil sociodemográficos e psiquiátrico de mulheres usuárias de substâncias psicoativas em tratamento para dependência química. Método: estudo descritivo de abordagem quantitativa realizado com mulheres atendidas em um Centro de Atenção Psicossocial para Usuários de Álcool e outras Drogas (CAPS ad) do interior paulista. Resultados: a amostra foi de 349 mulheres adultas, solteiras, baixa escolaridade e desempregadas, usuárias de álcool, cocaína, crack e tranquilizantes. Entre as consequências do uso incluem a síndrome de abstinência, overdose, sintomas depressivos e suicidas. A maioria foi encaminhada para o tratamento pela família ou serviços de saúde. Quase 20% dessas mulheres já havia iniciado tratamentos anteriormente. Conclusão: Os resultados sugerem acentuada morbidade e elevados níveis de vulnerabilidade psicossocial, que requerem investigação minuciosa na admissão da usuária, além de danos associados ao uso, sintomas de abstinência e sintomas depressivos.

The American Academy of Psychiatry and the Law Practice Resource for Prescribing in Corrections.

The practice of prescribing in jails and prisons is often different from that in the community. Serious mental illness is common among inmates, and so are co-morbidities such as substance use, impulse-control, attention-deficit/hyperactivity, and personality disorders. Operational requirements, staffing, and the physical plant of the institution may complicate the provision of treatment according to community standards. Problems related to medication nonadherence, as well as the pursuit of medications for nonmedical reasons, are often seen in these settings and may be managed differently than they are elsewhere. Existing practice resources rarely account for these challenges. Pursuant to a recommendation by the Correctional Committee of the American Academy of Psychiatry and the Law (AAPL), the AAPL Council in May 2015 approved the creation of a task force charged with producing a document on prescribing in correctional facilities.Full Document: Tamburello A, Metzner J, Ferguson E, et al: AAPL practice resource for prescribing in corrections. Journal of the American Academy of Psychiatry and the Law Online Supplement 2018, 46 (2). Available at: http://www.jaapl.org/content/46/2_Supplement.

Elderly people with mental disorders: experiencing the use of psychotropic medicines.

OBJECTIVE: To interpret the experience of the elderly with mental disorder in the use of psychotropic medicines. METHOD: Qualitative study in the interpretative modality, supported by the Grounded Theory. It was carried out from interviews with 16 elderly people with mental disorder and six relatives, totaling 22 participants. RESULTS: In the experience of the use of psychotropic medicines, the elderly with mental disorders become aware of their condition, attribute meaning and establish strategies for the correct use. On the other hand, they express their dissatisfaction with being dependent on psychotropic medicines to live without symptoms, face their side effects and do not always use them correctly. CONCLUSION: The use of psychotropic medicines is a priority in the life of the elderly and, in view of the fragilities found, it is necessary a continuous monitoring of health professionals.

Elderly people with mental disorders: experiencing the use of psychotropic medicines / Ancianos con trastornos mentales: vivenciando el uso de psicofármacos / Idosos com transtornos mentais: vivenciando o uso de psicofármacos

ABSTRACT Objective: To interpret the experience of the elderly with mental disorder in the use of psychotropic medicines. Method: Qualitative study in the interpretative modality, supported by the Grounded Theory. It was carried out from interviews with 16 elderly people with mental disorder and six relatives, totaling 22 participants. Results: In the experience of the use of psychotropic medicines, the elderly with mental disorders become aware of their condition, attribute meaning and establish strategies for the correct use. On the other hand, they express their dissatisfaction with being dependent on psychotropic medicines to live without symptoms, face their side effects and do not always use them correctly. Conclusion: The use of psychotropic medicines is a priority in the life of the elderly and, in view of the fragilities found, it is necessary a continuous monitoring of health professionals.

RESUMEN Objetivo: Interpretar la vivencia de ancianos con trastorno mental en la utilización de psicofármacos. Método: Estudio cualitativo en la modalidad interpretativa, apoyado por la Teoría Fundamentada en los Datos. Se realizó a partir de entrevistas con 16 ancianos con trastorno mental y seis familiares, totalizando 22 participantes. Resultados: En la vivencia del uso de psicofármacos, los ancianos con trastornos mentales toman conciencia de su condición, atribuyen significado y establecen estrategias para el uso correcto. En cambio, ellos expresan su descontento por depender de los psicofármacos para vivir sin síntomas, enfrentan sus efectos colaterales y ni siempre los utilizan de forma correcta. Conclusión: El uso de psicofármacos se constituye en prioridad en la vida de los ancianos y, frente a las fragilidades encontradas, es necesario un acompañamiento continuo de los profesionales de la salud.

RESUMO Objetivo: Interpretar a vivência de idosos com transtorno mental na utilização de psicofármacos. Método: Estudo qualitativo na modalidade interpretativa, apoiado pela Teoria Fundamentada nos Dados. Foi realizado a partir de entrevistas com 16 idosos com transtorno mental e seis familiares, totalizando 22 participantes. Resultados: Na vivência do uso de psicofármacos, os idosos com transtornos mentais tomam consciência da sua condição, atribuem significado e estabelecem estratégias para o uso correto. Em contrapartida, eles expressam o descontentamento por depender dos psicofármacos para viver sem sintomas, enfrentam seus efeitos colaterais e nem sempre os utilizam de forma correta. Conclusão: O uso de psicofármacos se constitui em prioridade na vida dos idosos e, frente às fragilidades encontradas, é necessário um acompanhamento contínuo dos profissionais de saúde.

[Treatment with psychotropic agents in patients with dementia and delirium : Gap between guideline recommendations and treatment practice]. / Psychopharmakotherapie bei Demenz und Delir : Im Spannungsfeld zwischen Leitlinienempfehlungen und Versorgungspraxis.

BACKGROUND AND OBJECTIVES: Psychiatric symptoms in dementia and delirium are associated with a substantially reduced quality of life of patients and their families and often challenging for professionals. Pharmacoepidemiological surveys have shown that, in particular, patients living in nursing homes receive prescriptions of psychotropic agents in significant higher frequency than recommended by current guidelines. This article focuses on a critical appraisal of this gap from the point of view of German healthcare services. MATERIAL AND METHODS: Narrative review with special reference to the German dementia guideline from 2016 and recently published practice guidelines for delirium in old age in German and English language. RESULTS: The indications for use of psychotropic agents, especially antipsychotics, are defined narrowly in the German dementia guideline. According to this guideline for several psychopathological symptoms evidence based recommendations cannot be given, currently. For delirium several practice guidelines related to different treatment settings have been published recently. Comparable to the German dementia guideline they recommend general medical interventions and nonpharmacological treatment as first line measures and the use of psychotropic agents only under certain conditions. These guidelines differ to some extent regarding the strength of recommendation for psychopharmacological treatment. CONCLUSION: The guidelines discussed here advocate well-founded a cautious prescription of psychotropic agents in patients with dementia and delirium. This contrasts to everyday practice which is characterized by significantly higher prescription rates. This gap may explained partially by a lack of evidence-based recommendations regarding certain psychopathological symptoms. Most notably, however, epidemiological data disclose an unacceptable rate of hazardous overtreatment with psychotropic agents, especially in long-term care of persons with dementia. In this situation counteractive measures by consequent implementation of the principles of good clinical practice in geriatrics are required urgently.

Stability of dronabinol capsules when stored frozen, refrigerated, or at room temperature.

PURPOSE: Results of a study to determine the 90-day stability of dronabinol capsules stored under various temperature conditions are reported. METHODS: High-performance liquid chromatography (HPLC) with ultraviolet (UV) detection was used to assess the stability of dronabinol capsules (synthetic delta-9-tetrahydrocannabinol [Δ9-THC] mixed with high-grade sesame oil and other inactive ingredients and encapsulated as soft gelatin capsules) that were frozen, refrigerated, or kept at room temperature for three months. The dronabinol capsules remained in the original foil-sealed blister packs until preparation for HPLC-UV assessment. The primary endpoint was the percentage of the initial Δ9-THC concentration remaining at multiple designated time points. The secondary aim was to perform forced-degradation studies under acidic conditions to demonstrate that the HPLC-UV method used was stability indicating. RESULTS: The appearance of the dronabinol capsules remained unaltered during frozen, cold, or room-temperature storage. Regardless of storage condition, the percentage of the initial Δ9-THC content remaining was greater than 97% for all evaluated samples at all time points over the three-month study. These experimental data indicate that the product packaging and the sesame oil used to formulate dronabinol capsules efficiently protect Δ9-THC from oxidative degradation to cannabinol; this suggests that pharmacies can store dronabinol capsules in nonrefrigerated automated dispensing systems, with a capsule expiration date of 90 days after removal from the refrigerator. CONCLUSION: Dronabinol capsules may be stored at room temperature in their original packaging for up to three months without compromising capsule appearance and with minimal reduction in Δ9-THC concentration.

[Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy]. / Bedeutung des Arzneimittelmarktneuordnungsgesetzes für die Psychopharmakotherapie.

The German Act on the Reform of the Market for Medicinal Products (AMNOG) will lead to rapid disappearance of many new psychotropic drugs from the market in Germany over the next few years or their not being introduced in the first place. This article lists the reasons and discusses possible solutions. In the long term, the AMNOG could not only lead to an improvement of psychopharmacology but also contribute to the development of psychiatry as a whole, especially if its standards become an international reference.

Patient-Important Outcomes in the Long-Term Treatment of Bipolar Disorder: A Mixed-Methods Approach Investigating Relative Preferences and a Proposed Taxonomy.

BACKGROUND: In patient-centered healthcare, the assessment and selection of treatment should be based on outcomes important to patients and the relative importance patients place on these outcomes. The evidence base on long-term treatment outcomes important to patients with bipolar disorder is inconclusive. OBJECTIVE: The aim of this study was to investigate the relative importance of patient-important outcomes in bipolar disorder, and to construct a holistic and logically sound shortlist of treatment outcomes relevant in the evaluation and selection of pharmacological treatment in bipolar disorder. METHOD: Overall, 22 outpatients from southern and eastern Norway participated in four focus groups, and suggested outcomes important in treatment decisions. Quantitative, relative importance weights for treatment outcomes identified in literature reviews were elicited from each participant, employing a self-explicated approach (SEA). The method combined a ranking- and rating-stated preference exercise and resulted in a 0-100 SEA-score for each outcome. RESULTS: Outcomes from the literature accommodated the outcomes suggested in the focus groups. Mean age in the sample was 42 years and 64% were women. All patients completed the exercises with consistent results. The most important outcomes were severe depression (median SEA 95 [interquartile range 26]), severe mania (76 [40]), quality of life (65 [53]), work/school functioning (58 [48]), and social functioning (54 [50]). Avoiding severe mania was significantly more important to patients with bipolar disorder type I compared with patients with type II. Outcome scores correlated strongly (p < 0.01) across the ranking and rating exercises. Based on the results, a simplified and consistent set of outcomes was constructed. CONCLUSIONS: Patients' preferences for outcomes in the long-term treatment of bipolar disorder vary considerably. To advance patient-centered healthcare, we propose that researchers, clinical guideline producers, and patient-clinician dyads integrate a taxonomy of patient-important outcomes, such as constructed in this study, when assessing treatment options.

[Transition of Psychotropic Drugs in Japanese Pharmacopoeia (JP) (Part 15). Transitions in the Standards and Test Methods of Potassium Bromide in JP I (1886) and JP X VI (2011), and Comparison between the USP and BP].

In mental clinics, bromide agents such as potassium bromide were often once used as therapeutic drugs to treat psychiatric disorders. They were also given as hypnotic, sedative and antiepileptic medicines. However, the appearance of new medicines has resulted in them not being used for these purposes in recent years. Potassium bromide is still continuously listed in today's JP and BP. This suggests that it maintains value as a basic medicine for treating mental disorders in the history of psychotropic medicines. However, regarding the standards and test methods for potassium bromide in the present JP, as a result of a comparison between the USP of the same age, BP and EP, a gap is seen, and this is very regrettable. The exchange of art and scientific information related to medical sciences with foreign countries is becoming more active today. Therefore, scholarly information overseas should be collected and reflected in the standards and test methods for potassium bromide adopted in the JP of Japan. The author believes that the standards and test methods comparable to those at the international level should introduced. On the other hand, potassium bromide was recetnly relisted by USP29 (2006) for the first time in approximately 50 years. Moreover, instrumental analysis was introduced as part of the test methods in BP2013; that is, an epoch-making revision was made in terms of test methods. It is assumed from this that there is a sign of new change regarding the existence of potassium bromide as hypnotic, sedative and antiepileptic medicines, and its utility value. It is believed that the sign of change in view of the utility value and pharmacological evaluation probably arose with the new clinical knowledge that potassium bromide was used to treat a baby seriously ill with myoclony epilepsy, as well as to treat a dog with epilepsy.

Psychotropic drug use among preschool children in the Medicaid program from 36 states.

OBJECTIVES: We determined the prevalence of and indications for psychotropic medication among preschool children in Medicaid. METHODS: We obtained 2000 to 2003 Medicaid Analytic Extract data from 36 states. We followed children in 2 cohorts, born in 1999 and 2000, up to age 4 years. We used logistic regression to model odds of receiving medications for (1) attention-deficit disorder/attention-deficit hyperactivity disorder, (2) depression or anxiety, and (3) psychotic illness or bipolar. RESULTS: Overall, 1.19% of children received at least 1 psychotropic drug. Medications for attention-deficit disorder/attention-deficit hyperactivity disorder treatment were most common (0.61% of all children), followed by depression or anxiety (0.59%) and psychotic illness or bipolar (0.24%). Among children, boys, those of other or unknown race compared with White, and those with other insurance compared with fee for service-only had higher odds of receiving a prescription (odds ratio [OR]=1.80 [95% confidence interval (CI)=1.74, 1.86], 1.75 [corrected] [1.66, 1.85], and 1.14 [1.01, 1.28], respectively), whereas Black and Hispanic children had lower odds (OR=0.51 [95% CI=0.48, 0.53] and 0.37 [0.34, 0.39], respectively). CONCLUSIONS: Preschoolers are receiving psychotropic medications despite limited evidence supporting safety or efficacy. Future research should focus on implementing medication use practice parameters in infant and toddler clinics, and expanding psychosocial interventions for young children with behavioral problems.

Prescribing in prison: minimizing psychotropic drug diversion in correctional practice.

Correctional facilities are a major provider of mental health care throughout the United States. In spite of the numerous benefits of providing care in this setting, clinicians are sometimes concerned about entering into correctional care because of uncertainty in prescribing practices. This article provides an introduction to prescription drug use, abuse, and diversion in the correctional setting, including systems issues in prescribing, commonly abused prescription medications, motivation for and detection of prescription drug abuse, and the use of laboratory monitoring. By understanding the personal and systemic factors that affect prescribing habits, the clinician can develop a more rewarding correctional practice and improve care for inmates with mental illness.

[Transitions of psychotropic drugs in the Japanese Pharmacopoeia (JP) (Part 14). Transitions in the standards and test methods of Valerian root in the Deutsches Arzneibuch (DAB) and comparison between the USP, BP, EP and JP, and Oleum Valerianae (Japan Kesso oil) listed in DAB6 (1926)].

Valerian has been used as a name for Japanese Valerian and European Valerian root. Valerian in the German market today was originally called Baldrian. Transitions in the standards and the test methods of Valerian root listed in the DAB were studied this time. Moreover, we compared these standards and test methods with those in the USP, BP, EP and JP. We also considered the pharmacology evaluation in Germany. At the time, the standards and test methods had content in accordance with the EP from DAB9 (1986) of the West Germany publication. It also agreed with the EP and BP of the same period. To date in the DAB, botanical features have been mainly derived from the discriminating characteristics of the Valerian root. In DAB9 (1986), standards and test methods were added to the content, enhancing it and making it more stringent. This is thought to have happened as a result of a new, academic finding showing an improvement in the pharmacology level. Valerian root has been listed continuously in the DAB. These listings suggest that Valerian root has continally been evaluated as a sedative. We think that the listing was connected with a relisting in the BP as a result of scientific communications between Britain and Germany, EC member nations, such as through EP publications. On the other hand, the oil made with Japanese Valerian was listed in a radical field in DAB6 (1926) in the past. This is a valuable result, proving that it was used and evaluated as an important herbal medicine from Japan and foreign countries at that time. The Japanese Valerian referred to is not grown in Japan today. Moreover, it is not possible that cultivation will be restarted through good quality revaluation. However, this fact introduces a valuable piece of history supporting the survival of Japanese Valerian and European Valerian root as a sedative in the future.